Mostrar o rexistro simple do ítem
Managing ulcerative colitis after surgery
dc.contributor.author | Calviño Suárez, Cristina | * |
dc.contributor.author | Ferreiro Iglesias, Rocio | * |
dc.contributor.author | Bastón Rey, Iria | * |
dc.contributor.author | Barreiro de Acosta, Manuel | * |
dc.date.accessioned | 2025-09-10T08:41:45Z | |
dc.date.available | 2025-09-10T08:41:45Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Calvino-Suarez C, Ferreiro-Iglesias R, Baston Rey I, Barreiro-de Acosta M. Managing ulcerative colitis after surgery. Vol. 9, Frontiers in Medicine. Frontiers Media S.A.; 2023. | |
dc.identifier.issn | 2296-858X | |
dc.identifier.other | https://portalcientifico.sergas.gal//documentos/63e7d77537a0683d533f67f6 | |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/21712 | |
dc.description.abstract | Management of ulcerative colitis after surgery suggested by guidelines (total proctocolectomy with ileal-pouch anal anastomosis) is a big challenge for physicians because patients who believed that their disease had been cured started experiencing very uncomfortable symptoms repeatedly. A high number of patients develop episodes of pouchitis, which is a non-specific inflammation of the pouch whose etiology is unknown. Antibiotics are the elective treatment for acute pouchitis, but regarding chronic pouchitis, this condition is very complicated to treat due to the absence of well-designed specific studies for this group of patients. Antibiotics, budesonide, and biological therapies are some of the recommended drugs for these patients, but despite their use, some need a permanent ileostomy. | |
dc.description.sponsorship | CC-S has served as a speaker for or has received research funding from MSD, AbbVie, Janssen, Takeda, and Adacyte. RF-I has served as a speaker for or has received research funding from Takeda, MSD, Abbvie, Janssen, Pfizer, Palex, Shire Pharmaceuticals, Tillotts Pharma, Dr. Falk Pharma, Ferring, Adacyte, and Casenrecordati. IB has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Janssen, Takeda, Pfizer, Faes Farma, and Adacyte. MB-d has served as an advisory board member for and has received financial support for research and/or training activities from MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Galapagos, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro, and Adacyte. | |
dc.language | eng | |
dc.rights | Attribution 4.0 International (CC BY 4.0) | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Managing ulcerative colitis after surgery | |
dc.type | Artigo | |
dc.authorsophos | Calvino-Suarez, C.; Ferreiro-Iglesias, R.; Baston Rey, I.; Barreiro-de Acosta, M. | |
dc.identifier.doi | 10.3389/fmed.2022.1081940 | |
dc.identifier.sophos | 63e7d77537a0683d533f67f6 | |
dc.journal.title | Frontiers in Medicine | * |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Dixestivo | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Dixestivo | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Dixestivo | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Dixestivo | |
dc.relation.projectID | MSD | |
dc.relation.projectID | AbbVie | |
dc.relation.projectID | Janssen | |
dc.relation.projectID | Takeda | |
dc.relation.projectID | Adacyte | |
dc.relation.projectID | Pfizer | |
dc.relation.projectID | Palex | |
dc.relation.projectID | Shire Pharmaceuticals | |
dc.relation.projectID | Tillotts Pharma | |
dc.relation.projectID | Dr. Falk Pharma | |
dc.relation.projectID | Ferring | |
dc.relation.projectID | Casenrecordati | |
dc.relation.projectID | Faes Farma | |
dc.relation.projectID | Kern Pharma | |
dc.relation.projectID | Biogen | |
dc.relation.projectID | Galapagos | |
dc.relation.projectID | Lilly | |
dc.relation.projectID | Chiesi | |
dc.relation.projectID | Gebro | |
dc.relation.publisherversion | https://doi.org/10.3389/fmed.2022.1081940 | |
dc.rights.accessRights | openAccess | * |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | CHUS | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | CHUS | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | CHUS | |
dc.subject.keyword | AS Santiago | |
dc.subject.keyword | CHUS | |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | |
dc.typesophos | Artículo de Revisión | |
dc.volume.number | 9 |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution 4.0 International (CC BY 4.0)
